PMID- 30210823
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 10
IP  - Suppl 23
DP  - 2018 Aug
TI  - Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss 
      National Registry.
PG  - S2711-S2718
LID - 10.21037/jtd.2018.04.53 [doi]
AB  - BACKGROUND: Endobronchial coils have been demonstrated in three randomized, 
      controlled trials to improve quality of life, exercise tolerance, and lung 
      function in patients with severe emphysema. This therapy is CE-marked and 
      commercially available in Switzerland. Coil treated patients are followed in a 
      post-market Swiss registry to collect safety and effectiveness data in routine 
      clinical practice. METHODS: The Swiss coil registry was initiated in October 
      2013. At the end of November 2016, an interim analysis of all 64 patients treated 
      in five centers was performed to evaluate safety and effectiveness at six months 
      post treatment. RESULTS: patients had completed bilateral treatment with 6-month 
      follow up at the time of data analysis. Patients had very severe, symptomatic 
      emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% 
      pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, 
      St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following 
      treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No 
      device removals were necessary. At 6 months, responder rates [% achieving the 
      minimal clinically important difference (MCID)] were as follows: RV (-0.35 L) 
      76%; FEV1 (+10%) 57%; SGRQ (-4 points) 87%; 6MWD (+26 m) 60%. CONCLUSIONS: 
      Endobronchial coil therapy performed in expert centers in Switzerland yields high 
      6-month responder rates across all relevant outcome.
FAU - Fellrath, Jean-Marc
AU  - Fellrath JM
AD  - Department of Pulmonary Medicine, Pourtales Hospital, Neuchatel, Switzerland.
FAU - Scherer, Thomas
AU  - Scherer T
AD  - LungenZentrum Hirslanden, Zurich, Switzerland.
FAU - Franzen, Daniel P
AU  - Franzen DP
AD  - Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Lovis, Alban
AU  - Lovis A
AD  - Pneumology Division, Centre Hospitalier Universitaire Vaudois, Lausanne, 
      Switzerland.
FAU - von Garnier, Christophe
AU  - von Garnier C
AD  - Respiratory Medicine Department, Inselspital, University of Bern, Bern, 
      Switzerland.
FAU - Plojoux, Jerome
AU  - Plojoux J
AD  - Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland.
FAU - Soccal, Paola M
AU  - Soccal PM
AD  - Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland.
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC6129812
OTO - NOTNLM
OT  - Chronic obstructive pulmonary disease (COPD)
OT  - bronchoscopic lung volume reduction
OT  - coils
OT  - emphysema
OT  - registry
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2018/09/14 06:00
MHDA- 2018/09/14 06:01
PMCR- 2018/08/01
CRDT- 2018/09/14 06:00
PHST- 2018/09/14 06:00 [entrez]
PHST- 2018/09/14 06:00 [pubmed]
PHST- 2018/09/14 06:01 [medline]
PHST- 2018/08/01 00:00 [pmc-release]
AID - jtd-10-S23-S2711 [pii]
AID - 10.21037/jtd.2018.04.53 [doi]
PST - ppublish
SO  - J Thorac Dis. 2018 Aug;10(Suppl 23):S2711-S2718. doi: 10.21037/jtd.2018.04.53.